Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCL-2 Inhibitors + HyperCVAD for Newly Diagnosed T-ALL/LBL
NCT06598722Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in T-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by Shanghai General Hospital. Started Aug 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT06598722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598722.